← Azimuth Daily
Capturing data…
Capturing data…
TUE, 22 SEPT · 78 ITEMS
"Lilly's breast cancer combination therapy approved by FDA" — STAT News · Science & Medicine
The FDA approved Eli Lilly's combination therapy for advanced breast cancer — specifically the oral imlunestrant (brand name Inluriyo) paired with the abemaciclib. The approval covers , ESR1-mutated , and a (Guardant360 CDx) was also cleared to identify eligible patients. This is a second-line treatment option that roughly doubled progression-free survival in the underlying trial.
The claim is solid and well-corroborated: the FDA's own approval announcement, a Reuters wire, and Lilly's investor release all confirm the approval and the drug combination. The STAT News piece is secondary aggregation, but it sits close to primary sources (FDA and Lilly), so the core facts are reliable; the specific survival-doubling detail comes from trial data reported in secondary coverage, not from the primary label.
This is genuinely new: the FDA approval was announced in the 2026-09-18 to 2026-09-21 window, with STAT's piece published on 2026-09-21.
We covered the FDA approval of AstraZeneca's breast-cancer pill in early September 2026, which is a different drug but the same disease area and regulatory context.